First-in-class, Dual-action, Pan-cancer Therapy
— Powered by USP22 Inhibition
> 3M
Newly Diagnosed Patients Worldwide with
Breast, Lung, Skin, Colon, or Liver Cancer
FAIL First-line Treatment Every Year
- Directly Targeted by Our Therapy
> 4M
Lives Are Lost Worldwide to
These Cancers We Treat.
For them, the Sun Set
- And NEVER Rose Again.
ExoMira’s Flagship Cancer Therapy:
USP22 Inhibitors with Dual Cancer-killing Mechanisms
- Tumor Suppression & Immune Activation
Let Science Speak
ExoMira Medicine’s flagship therapy is a USP22 inhibitor – a targeted small molecule that delivers a “one-two punch” to tumors. USP22 is a deubiquitinating enzyme overexpressed in many aggressive cancers, where it helps tumor cells survive and promotes immune evasion.
In tumor cells, USP22 acts as an oncogenic driver: it stabilizes proteins that cancer cells need for growth (like Sirt1, CCNB1 and CCND1), enabling unchecked proliferation and resistance to cell death. By inhibiting USP22, ExoMira’s compound triggers cancer cells to self-destruct and blocks pathways of metastasis.
At the same time, in the tumor microenvironment, USP22 is a linchpin of immune suppression: it protects FOXP3, the master regulator in regulatory T cells (Tregs), preventing these Tregs from being degraded. Tumor-infiltrating Tregs typically act as bodyguards for the cancer, suppressing the attack by killer T cells. ExoMira’s USP22 inhibitor flips this script – blocking USP22 causes Tregs to lose their fitness and suppressive function, freeing CD8⁺ T cells and NK cells to assault the tumor.
In essence, our medicine simultaneously destroys tumor cells and lifts the tumor’s immune shield, functioning as both a direct chemotherapy and an immunotherapy in a single agent.
Why We Are Unique
-
Dual Mechanism
Most cancer therapies choose a lane — tumor or immune — and fail. Our proprietary USP22i products do both, in one integrated approach.
-
Superior Safety Profile
Engineered for precision, our USP22 inhibitors avoid the widespread immune toxicity seen with many current and experimental options.
-
Broad Pan-Cancer Potential
USP22 is overexpressed across many cancers, giving our therapy built-in versatility to expand into multiple high-need, deadly tumor types.
ExoMira Core Leadership
-
Dr. Deyu Fang
MD, PhD
Co-founder -
Dr. Huiping Liu
MD, PhD
President, Co-founder -
Dr. Andrew Hoffmann
PhD
Chief Scientific Officer -
Yan He
MBA, MSc
Director, Business & Clinical Development -
Dr. Alex Le
PhD, EMBA
Executive Advisor
Strategic Partners & Supporters
Contact Us
ExoMira Medicine Inc. (“ExoMira”) is a Chicago-based preclinical-stage pharmaceutical startup (a spin-off from Northwestern University) focused on developing innovative cancer immunotherapies.
If you would like to get in touch with us, feel free to complete the contact form below or send us an email to facilitate a career or business partnership. We look forward to connecting with you.
Our general inquiry email: info@exomira.com
